Guidance on the use of the benchmark dose approach in risk assessment

The Scientific Committee (SC) reconfirms that the benchmark dose (BMD) approach is a scientifically more advanced method compared to the no‐observed‐adverse‐effect‐level (NOAEL) approach for deriving a Reference Point (RP). The major change compared to the previous Guidance (EFSA SC, 2017) concerns...

Descripción completa

Detalles Bibliográficos
Autores principales: More, Simon John, Bampidis, Vasileios, Benford, Diane, Bragard, Claude, Halldorsson, Thorhallur Ingi, Hernández‐Jerez, Antonio F, Bennekou, Susanne Hougaard, Koutsoumanis, Kostas, Lambré, Claude, Machera, Kyriaki, Mennes, Wim, Mullins, Ewen, Nielsen, Søren Saxmose, Schrenk, Dieter, Turck, Dominique, Younes, Maged, Aerts, Marc, Edler, Lutz, Sand, Salomon, Wright, Matthew, Binaglia, Marco, Bottex, Bernard, Abrahantes, Jose Cortiñas, Schlatter, Josef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Guidance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593753/
https://www.ncbi.nlm.nih.gov/pubmed/36304832
http://dx.doi.org/10.2903/j.efsa.2022.7584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593753/
https://www.ncbi.nlm.nih.gov/pubmed/36304832
http://dx.doi.org/10.2903/j.efsa.2022.7584

Ejemplares similares